Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to -$1.3 million.

  • Ocular Therapeutix's Cash from Investing Activities fell 6633.71% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.2 million, marking a year-over-year decrease of 498.25%. This contributed to the annual value of -$1.3 million for FY2024, which is 78.84% up from last year.
  • According to the latest figures from FY2024, Ocular Therapeutix's Cash from Investing Activities is -$1.3 million, which was up 78.84% from -$6.1 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Cash from Investing Activities registered a high of -$841,000 during FY2020, and its lowest value of -$6.1 million during FY2023.
  • In the last 3 years, Ocular Therapeutix's Cash from Investing Activities had a median value of -$3.7 million in 2022 and averaged -$3.7 million.
  • Per our database at Business Quant, Ocular Therapeutix's Cash from Investing Activities slumped by 211.14% in 2022 and then soared by 78.84% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Cash from Investing Activities (Yearly) stood at -$841,000 in 2020, then plummeted by 41.97% to -$1.2 million in 2021, then tumbled by 211.14% to -$3.7 million in 2022, then slumped by 63.85% to -$6.1 million in 2023, then soared by 78.84% to -$1.3 million in 2024.